再生医療の世界市場:細胞治療、組織スキャフォールド、遺伝子治療

◆英語タイトル:Global Regenerative Medicine Market 2016-2020
◆商品コード:IRTNTR9465
◆発行会社(調査会社):Technavio
◆発行日:2016年5月16日
◆ページ数:117
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、再生医療の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、再生医療の世界市場規模及び予測、用途別分析、製品別分析、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About the Regenerative Medicine Market
Regenerative medicine is a process of regenerating cells, tissues, and organs to restore normal function in a diseased organ. This branch of tissue engineering and molecular biology is promising and is driven by demand from patients, development of cell therapy, tissue scaffold, and gene therapy products, and increase in the number of pipeline products.

Technavio’s analysts forecast the global regenerative medicine market to grow at a CAGR of 20.7% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global regenerative medicine market for 2016-2020. To calculate the market size, we used the revenue generated from the sales of various types of regenerative medicine products.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Regenerative Medicine Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Acelity
• Medtronic
• MiMedx Group
• Organogenesis
• UniQure
• Zimmer Biomet

[Other prominent vendors]
• ACE Surgical Supply
• Acologix
• Advanced Biologics
• AlloCure
• Allosource
• Alphatec Spine
• Altrika
• Amorcyte
• Anterogen
• Antibe Therapeutics
• Astellas Pharma
• Athersys
• Avita Medical
• AxoGen
• Bacterin International
• Baxter
• Bellicum Pharmaceuticals
• BioCardia
• Biogen Idec
• BioRestorative Therapies
• Biostage Technologies
• Bluebird Bio
• BONESUPPORT
• BrainStorm Cell Therapeutics
• Caladrius Biosciences
• Calimmune
• Capricor Therapeutics
• Celgene
• Cell Medica
• CellSeed
• Cell Therapy
• Celyad
• CESCA THERAPEUTICS
• CRC for Cell Therapy Manufacturing
• Cryolife
• Cynata Therapeutics
• Cytori Therapeutics
• Dendreon
• DiscGenics
• Fate Therapeutics
• Fibrocell Science
• Forticell Bioscience
• Fortress Biotech
• FUJIFILM
• Gamida Cell
• Geron
• GlaxoSmithKline
• Healthpoint
• Histogen
• Histogenics
• Holostem Terapie Avanzate
• Humacyte
• ImmunoCellular Therapeutics
• Integra LifeSciences
• Intercytex
• InVivo Therapeutics
• iSTO Technologies
• Janssen Pharma
• Juno Therapeutics
• Juventas Therapeutics
• Kensey Nash
• Kiadis Pharma
• Kinetic Concept
• LifeCell
• LifeNet Health
• Living Cell Technologies
• Lonza
• MaxCyte
• MEDIPOST
• Mesoblast
• Nanofiber Solutions CTO
• Nanotope
• NeoStem
• Neuralstem
• Newlink Genetics
• Northwest Biotherapeutics
• NovaRx
• Ocata Therapeutics
• Opexa Therapeutics
• Organovo Holdings
• Orteg
• Orthofix
• Osiris Therapeutics
• Osteotech
• Pfizer
• Pharmicell
• Pluristem Therapeutics
• Prima BioMed
• Q Therapeutics
• Regenerex
• Regenerys
• Regience
• Regrow
• Replicel
• ReproCELL
• Renova Therapeutics
• RhinoCyte
• Rohto Pharmaceutical
• RTI Surgical
• SanBio
• Sangamo BioSciences
• Shanghai Sunway Biotech
• Shire Regenerative Medicine
• StemCells
• Stratech
• Takara Bio
• TEI Biosciences
• tella
• Tengion
• Tissue Genesis
• TissueGene
• Txcell
• VentriNova
• Vericel
• ViaCyte
• Vistagen

[Market driver]
• Increased focus on cell therapy products
• For a full, detailed list, view our report

[Market challenge]
• High cost and failure rate in clinical trials
• For a full, detailed list, view our report

[Market trend]
• Increased number of regenerative medicine in product line
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Pipeline portfolio
• Pipeline analysis

PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 07: Market segmentation by product
• Cell therapy
• Ethical issues of stem cell research
• Global cell therapy market
• Tissue scaffold
• Global tissue scaffold market
• Gene therapy
• Gene therapy market in Europe

PART 08: Market segmentation by application
• Dermatology
• Musculoskeletal
• Ocular
• Cardiovascular

PART 09: Geographical segmentation
• Regenerative medicine market in Americas
• Regenerative medicine market in EMEA
• Regenerative medicine market in APAC

PART 10: Market drivers
• Increased prevalence of chronic diseases
• Funding by governments in regenerative medicine
• Increased focus on cell therapy products
• Technological innovations

PART 11: Impact of drivers

PART 12: Market challenges
• Stringent regulatory standards impeding product approvals
• Ethical challenges in stem cell research
• High cost and failure rate in clinical trials

PART 13: Impact of drivers and challenges

PART 14: Market trends
• Increase in strategic alliances
• Increased number of regenerative medicine in the pipeline
• Gene therapy trending toward geographic expansion

PART 15: Vendor landscape
• Competitive scenario
• Acelity
• Medtronic
• MiMedx Group
• Organogenesis
• UniQure
• Zimmer Biomet
• Other prominent vendors

PART 16: Appendix
• List of abbreviations

PART 17: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Overview of key sectors involved in regenerative medicine
Exhibit 03: Key sectors in regenerative medicine 2015
Exhibit 04: SBIR and STTR programs
Exhibit 05: Clinical trials 2014
Exhibit 06: Number of clinical trials and products in regenerative medicine market 2014
Exhibit 07: Pipeline of regenerative medicines for CVDs
Exhibit 08: Pipeline of regenerative medicines for central nervous system, orthopedic, and ocular disorders
Exhibit 09: Pipeline of regenerative medicines for dermatology and diabetes
Exhibit 10: Pipeline of regenerative medicines for oncology
Exhibit 11: Global regenerative medicine market 2015-2020 ($ billions)
Exhibit 12: Five forces analysis
Exhibit 13: Global regenerative medicine market by product
Exhibit 14: Global regenerative medicine market by product 2015
Exhibit 15: Cell therapy: Overview
Exhibit 16: Ethical issues faced in different cell therapy research category
Exhibit 17: Stem cell research policies in emerging countries in Americas
Exhibit 18: Stem cell research policies in EMEA
Exhibit 19: Stem cell research policies in APAC
Exhibit 20: Key cell therapy products marketed in the US
Exhibit 21: Key cell therapy products marketed in EMEA
Exhibit 22: Key marketed cell therapy products in APAC
Exhibit 23: Opportunity analysis of cell therapy in global regenerative medicine market
Exhibit 25: Collaborations for R&D of tissue scaffold
Exhibit 26: Opportunity analysis of tissue scaffold in regenerative medicine market
Exhibit 27: Global tissue scaffold market 2015-2020 ($ billions)
Exhibit 28: Recent M&A in tissue scaffold market
Exhibit 29: Gene therapy products in Europe
Exhibit 30: Opportunity analysis of gene therapy in global regenerative medicine market
Exhibit 31: Gene therapy market in Europe 2015-2020 ($ billions)
Exhibit 32: European Commission support in gene transfer and gene therapy projects
Exhibit 33: Global regenerative medicine market by application
Exhibit 34: Global regenerative medicine market by application 2015
Exhibit 35: Overview of dermatology segment in global regenerative medicine market
Exhibit 36: Pipeline of regenerative medicine for dermatology
Exhibit 37: Overview of musculoskeletal segment in global regenerative medicine market
Exhibit 38: Overview of ocular segment in global regenerative medicine market
Exhibit 39: Overview of cardiovascular segment in global regenerative medicine market
Exhibit 40: Global regenerative medicine market by geography 2015
Exhibit 41: Global regenerative medicine market by geography 2020
Exhibit 42: Funding by federal agencies for R&D of regenerative medicine 2014 ($ millions)
Exhibit 43: Regenerative medicine market in Americas 2015-2020 ($ billions)
Exhibit 44: Distribution of 45 cell therapy vendors in Europe 2011
Exhibit 45: Regenerative medicine market in EMEA 2015-2020 ($ billions)
Exhibit 46: Regenerative medicine market in APAC 2015-2020 ($ billions)
Exhibit 47: Key developments in regenerative medicine market in Japan 2015
Exhibit 48: Global regenerative medicine market by geography 2015-2020
Exhibit 49: Global regenerative medicine market by geography 2015-2020 ($ billions)
Exhibit 50: Breakdown of CIRM funding in various stem cell research studies 2014 ($ billions)
Exhibit 51: Active programs under CIRM 2014
Exhibit 52: Funding by European Commission for regenerative medicine
Exhibit 53: Impact of drivers
Exhibit 54: Impact of drivers and challenges
Exhibit 55: Major strategic alliances in global regenerative medicine market
Exhibit 56: Mid- and late-stage pipeline products for regenerative medicine
Exhibit 57: Clinical trials on gene therapy for various indications
Exhibit 58: Vendors in global regenerative medicine market
Exhibit 59: Acelity: Business segmentation by revenue 2015
Exhibit 60: Acelity: Regenerative medicine revenues and YoY growth rate 2013-2015 ($ millions)
Exhibit 61: Acelity: Metrics analysis
Exhibit 62: Medtronic: Metrics analysis
Exhibit 63: MiMedx Group: Metrics analysis
Exhibit 64: Organogenesis: Metrics analysis
Exhibit 65: UniQure: Metrics analysis
Exhibit 66: Zimmer Biomet: Metrics analysis
Exhibit 67: Other prominent vendors



【掲載企業】

Acelity, Medtronic, MiMedx Group, Organogenesis, UniQure, ZimmerBiomet, ACE Surgical Supply, Acologix, Advanced Biologics, AlloCure, Allosource, Alphatec Spine, Altrika, Amorcyte, Anterogen, Antibe Therapeutics, Astellas Pharma, Athersys, Avita Medical, AxoGen, Bacterin International, Baxter, Bellicum Pharmaceuticals, BioCardia, Biogen Idec, BioRestorative Therapies, Biostage, BioTissue Technologies, Bluebird Bio, BONESUPPORT, BrainStorm Cell Therapies, Caladrius Biosciences, Calimmune, Capricor Therapeutics, Celgene, Cell Medica, CellSeed, Cell Therapy, Celyad, CESCA THERAPEUTICS, CRC for Cell Therapy Manuracturing, Cryolife, Cynata Therapeutics, Cytori Therapeutics, Dendreon, DiscGenics, Fate Therapeutics, Fibrocell Science, Forticell Bioscience, Fortress Biotech, FUJIFILM, Gamida Cell, Geron, GlaxoSmithKline, Healthpoint, Histogen, Histogenics, Holostem Terapie Avanzate, Humacyte, ImmunoCellular Therapeutics, Integra LifeSciences, Intercytex, InVivo Therapeutics, iSTO Technologies, Janssen Pharma, Juno Therapeutics, Juventas Therapeutics, Kensey Nash, Kiadis Pharma, Kinetic Concept, LifeCell, LifeNet Health, Living Cell Technologies, Lonza, MaxCyte, MEDIPOST, Mesoblast, Nanofiber Solutions CTO, Nanotope, NeoStem, Neuralstem, Newlink Genetics, Northwest Biotherapeutics, NovaRx, Ocata, Opexa Therapeutics, Organovo Holdings, Orteg, Orthofix, Osiris Therapeutics, Osteotech, Pfizer, Pharmicell, Pluristem Therapeutics, PrimaBioMed, Q Therapeutics, Regenerex, Regenerys, Regience, Regrow, RepliCel, ReproCELL, Renova Therapeutics, RhinoCyte, Rohto Pharmaceutical, RTI Surgical, SanBio, Sangamo BioSciences, Shanghai Sunway Biotech, Shire Regenerative Medicine, StemCells, Stratatech, Takara Bio, TEI Biosciences, tella, Tengion, Tissue Genesis, TissueGene, Txcell, VentriNova, Vericel, ViaCyte, Vistagen.

【レポートのキーワード】

再生医療、細胞治療、組織スキャフォールド、遺伝子治療、幹細胞、皮膚病学、筋骨格、眼、心血管

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[再生医療の世界市場:細胞治療、組織スキャフォールド、遺伝子治療]販売に関する免責事項
★調査レポート[再生医療の世界市場:細胞治療、組織スキャフォールド、遺伝子治療]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆